Accessibility Menu
 
","image":{"@type":"ImageObject","url":"http://g.foolcdn.com/avatar/1706180953/large.ashx","height":"80","width":"80"}},"about":[{"@type":"Corporation","tickerSymbol":"NYSE NVO"},{"@type":"Corporation","tickerSymbol":"AZN"}],"publisher":{"@type":"Organization","@id":"https://www.fool.com/","name":"The Motley Fool","url":"https://www.fool.com/","logo":{"@type":"ImageObject","url":"https://g.foolcdn.com/misc-assets/logo-tmf-primary-7-magenta-royalpurple.svg","width":"157","height":"43"},"brand":"The Motley Fool","contactPoint":{"@type":"ContactPoint","contactType":"Media Inquiries","email":"[email protected]"},"publishingPrinciples":"https://www.fool.com/about/","sameAs":["https://www.fool.com/about/","https://en.wikipedia.org/wiki/The_Motley_Fool","https://www.wikidata.org/wiki/Q7752442","https://www.linkedin.com/company/the-motley-fool","https://www.facebook.com/themotleyfool/","https://x.com/themotleyfool","https://www.instagram.com/themotleyfoolofficial/","https://www.youtube.com/channel/UCpRQuynBX9Qy9tPrcswpPag","https://www.pinterest.com/themotleyfool/","https://www.tiktok.com/@themotleyfoolofficial","https://www.google.com/search?kgmid=/m/0578mk"]},"description":"Novo Nordisk and AstraZeneca might be the first \"big pharma\" companies to market drugs for the treatment of obesity.","image":{"@type":"ImageObject","height":"630","width":"1200"}}","image":{"@type":"ImageObject","url":"http://g.foolcdn.com/avatar/1706180953/large.ashx","height":"80","width":"80"}},"inLanguage":"en-US"}

Will Big Pharma Dominate the Obesity Space?

Novo Nordisk and AstraZeneca might be the first "big pharma" companies to market drugs for the treatment of obesity.

By Max Macaluso and Dave Williamson Jul 14, 2013 at 1:00PM EST

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.